company background image
VCEL

Vericel NasdaqCM:VCEL Stock Report

Last Price

US$21.09

Market Cap

US$995.9m

7D

-1.0%

1Y

-43.5%

Updated

28 Nov, 2022

Data

Company Financials +
VCEL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance0/6
Financial Health6/6
Dividends0/6

VCEL Stock Overview

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States.

Vericel Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vericel
Historical stock prices
Current Share PriceUS$21.09
52 Week HighUS$43.97
52 Week LowUS$17.30
Beta1.99
1 Month Change-19.96%
3 Month Change-18.45%
1 Year Change-43.47%
3 Year Change11.35%
5 Year Change334.85%
Change since IPO-98.12%

Recent News & Updates

Vericel Corporation: Stock Has Fallen, But Not Enough To Make This A Buy

Oct 10

Recent updates

Calculating The Fair Value Of Vericel Corporation (NASDAQ:VCEL)

Apr 19
Calculating The Fair Value Of Vericel Corporation (NASDAQ:VCEL)

Vericel Corporation's (NASDAQ:VCEL) Intrinsic Value Is Potentially 19% Below Its Share Price

Aug 09
Vericel Corporation's (NASDAQ:VCEL) Intrinsic Value Is Potentially 19% Below Its Share Price

Statutory Profit Doesn't Reflect How Good Vericel's (NASDAQ:VCEL) Earnings Are

Mar 03
Statutory Profit Doesn't Reflect How Good Vericel's (NASDAQ:VCEL) Earnings Are

Is Vericel Corporation's (NASDAQ:VCEL) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Feb 26
Is Vericel Corporation's (NASDAQ:VCEL) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Shareholder Returns

VCELUS BiotechsUS Market
7D-1.0%0.2%0.3%
1Y-43.5%-16.1%-20.5%

Return vs Industry: VCEL underperformed the US Biotechs industry which returned -14.4% over the past year.

Return vs Market: VCEL underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is VCEL's price volatile compared to industry and market?
VCEL volatility
VCEL Average Weekly Movement12.3%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: VCEL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: VCEL's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1989281Nick Colangelohttps://vcel.com

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

Vericel Corporation Fundamentals Summary

How do Vericel's earnings and revenue compare to its market cap?
VCEL fundamental statistics
Market CapUS$995.93m
Earnings (TTM)-US$18.10m
Revenue (TTM)US$159.26m

6.3x

P/S Ratio

-55.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VCEL income statement (TTM)
RevenueUS$159.26m
Cost of RevenueUS$53.69m
Gross ProfitUS$105.57m
Other ExpensesUS$123.67m
Earnings-US$18.10m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.38
Gross Margin66.29%
Net Profit Margin-11.36%
Debt/Equity Ratio0%

How did VCEL perform over the long term?

See historical performance and comparison